David Craig is a pharmaceutical executive with more than 30 years of experience leading and scaling organizations to commercial success. Mr. Craig has been a member of, and led, teams responsible for the commercialization of blockbuster #1-in-market, or first-in-class, novel medicines including EPOGEN (erythropoietin alfa), NEUPOGEN (filgrastim), HEPSERA (adefovir dipivoxil) and ANDEXXA (andexanet afla). He has held leadership roles at Amgen, Sequus, Gilead Sciences, AcelRx, Portola, and the UNR Licensing Office. Mr. Craig earned a BS in Pharmacy from South Dakota State University and an MBA from the Pepperdine Graziadio Business School.